FIELD: biotechnology.
SUBSTANCE: method is proposed for the treatment of an oncological disease in a patient with target cells expressing FcγRIIb, characterized in that the patient is selected based on the expression of an increased level of FcγRIIb by his/her target cells. The method includes the injection of an antibody that specifically binds CD20 and has Fc domain capable of binding FcγRIIb in combination with an antibody specifically binding FcγRIIb. The invention also relates to a pharmaceutical composition for the implementation of the specified treatment method and to a method for predicting a response of patient’s target cells for the treatment of an oncological disease with target cells that express FcγRIIb. The prediction method includes the determination of a level of FcγRIIb expression on target cells. Increased levels of FcγRIIb are prognostic relatively to the reduction or absence of response for the treatment with an antibody specifically binding CD20 and having Fc domain capable of binding FcγRIIb.
EFFECT: invention allows for an increase of the efficiency of treatment of an oncological disease.
23 cl, 48 dwg, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | 2017 |
|
RU2772434C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO CONSTANT REGION OF β T-CELL RECEPTOR | 2015 |
|
RU2830064C2 |
| COVALENT DIABODIES AND USE THEREOF | 2009 |
|
RU2744176C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
